| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8b0f7418d61c850c44782b867bf7b16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
1998-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b593f2354b6064963d826fab913d0c88 |
| publicationDate |
1998-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9837897-A1 |
| titleOfInvention |
Method for reducing coronary artery reactivity |
| abstract |
A method for reducing coronary artery reactivity. A predetermined amount of natural progesterone is provided by a convenient and pleasant delivery system to the blood stream, sufficient to reduce the likelihood of coronary vasospasm and myocardial ischemia. The progesterone may be provided either by topical application to the epidermis of a cream in which the progesterone is dissolved or by patch technology, so as to provide continuous delivery and thereby maintain the level of progesterone in the blood stream at least about 1 nanogram per milliliter. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6747019-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7320970-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10150793-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7674783-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7604949-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7078394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10040816-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10259839-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0059577-A1 |
| priorityDate |
1997-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |